Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays by Yu, Jingyou et al.
1 
Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in 1 








, Makda S. Gebre
1,2
, Esther A. Bondzie
1





, David R. Martinez
4
, Joseph P. Nkolola
1









1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard 8 
Medical School, Boston, MA 02215, USA; 2Harvard Medical School, Boston, MA, 02115; 3Ragon 9 
Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; 4University of North Carolina at 10 
Chapel Hill, Chapel Hill, NC, 27599, USA 11 
* Corresponding author: Dan H. Barouch. Email: dbarouch@bidmc.harvard.edu12 
13 
Running title: Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Improves 14 
Pseudovirus Infectivity 15 
16 





JVI Accepted Manuscript Posted Online 16 March 2021
J Virol doi:10.1128/JVI.00044-21
Copyright © 2021 Yu et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
2 
ABSTRACT 22 
Pseudotyped viruses are valuable tools for studying virulent or lethal viral pathogens that need to be 23 
handled in biosafety level 3 (BSL-3) or higher facilities. With the explosive spread of the coronavirus 24 
disease 2019 (COVID-19) pandemic, the establishment of a BSL-2 adapted SARS-CoV-2 pseudovirus 25 
neutralization assay is needed to facilitate the development of countermeasures. Here we describe an 26 
approach to generate a single-round lentiviral vector-based SARS-CoV-2 pseudovirus, which produced a 27 
signal more than 2 logs above background. Specifically, a SARS-CoV-2 spike variant with a cytoplasmic 28 
tail deletion of 13 amino acids, termed SΔCT13, conferred enhanced spike incorporation into 29 
pseudovirions and increased viral entry into cells as compared with full-length spike (S). We further 30 
compared S and SΔCT13 in terms of their sensitivity to vaccine sera, purified convalescent IgG, hACE2-31 
mIgG, and the virus entry inhibitor BafA1. We developed a SΔCT13-based pseudovirus neutralization 32 
assay and defined key assay characteristics, including linearity, limit of detection, and intra- and 33 
intermediate-assay precision. Our data demonstrate that the SΔCT13-based pseudovirus shows enhanced 34 
infectivity in target cells, which will facilitate the assessment of humoral immunity to SARS-CoV-2 35 
infection, antibody therapeutics, and vaccination.  This pseudovirus neutralization assay can also be 36 
readily adapted to SARS-CoV-2 variants that emerge. 37 
38 
IMPORTANCE 39 
SARS-CoV-2 is the etiologic agent of the COVID-19 pandemic. The development of a high throughput 40 
pseudovirus neutralization assay is critical for the development of vaccines and immune-based 41 
therapeutics.  In this study, we show that deletion of the cytoplasmic tail of the SARS-CoV-2 spike leads 42 
to pseudoviruses with enhanced infectivity.  This SΔCT13-based pseudovirus neutralization assay should 43 
be broadly useful for the field. 44 
3 
INTRODUCTION 45 
The emerging pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute 46 
respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unprecedented need to develop vaccines 47 
and other countermeasures (1). To develop a successful vaccine candidate, identifying and screening the 48 
immune correlates of protection in a high-throughput assay is paramount. Neutralizing antibody responses 49 
may represent key immune correlates of protection for SARS-CoV-2 (2, 3). Therefore, it is essential to 50 
develop a high throughput in vitro neutralization assay that recapitulates key features of in vivo 51 
neutralizing activity. However, live SARS-CoV-2 research is restricted to biosafety level-3 (BSL-3) 52 
facilities, and traditional approaches such as plaque reduction assays are time-consuming and low-53 
throughput. 54 
Pseudotyped viruses have often been employed to evaluate the physiology of lethal viruses, such 55 
as Ebola virus (4), Marburg virus (5) and Lassa virus (6). Pseudoviruses encompass essential components 56 
for viral infection, typically the envelope proteins derived from viruses of interest and an inner core, but 57 
they lack intact viral genome and thus lose self-replication capacity (7). The conformational structure of 58 
pseudovirus surface proteins appears to resemble that of the native viral proteins (8), which may allow for 59 
a similar viral entry process between the pseudoviruses and infectious counterparts. As such, 60 
pseudoviruses are typically regarded as safe and effective virological tools. Pseudoviruses have been 61 
utilized for receptor identification, host tropism determination, and viral entry mechanistic studies (7); for 62 
identifying entry inhibitors by screening compound libraries (9); and for evaluating neutralizing antibody 63 
responses elicited by vaccination or from convalescent sera (10). Pseudoviruses may also be useful in 64 
assessments of antibody-dependent enhancement (11, 12). As such, it is important to develop a BSL2-65 
adapted SARS-CoV-2 pseudovirus system. 66 
SARS-CoV-2 encodes four structural proteins: spike (S), nucleocapsid (N), envelope (E) and 67 
membrane (M), and more than twenty non-structural proteins (13). S represents the only protein that 68 
mediates SARS-CoV-2 entry and serves as a key immunogen for inducing protective immunity (14). S is 69 
synthesized as a precursor in rough endoplasmic reticulum (ER) and further processed into amino-70 
4 
terminal S1 and carboxyl-terminal S2 segments, which contribute to receptor binding and cell fusion, 71 
respectively. S has been utilized for generating pseudoviruses for SARS-CoV (SARS-CoV-1) (15) and 72 
Middle East respiratory syndrome coronavirus (MERS-CoV) (16), two highly pathogenic and closely 73 
related human coronaviruses. As of now, multiple platforms have been leveraged to investigate SARS-74 
CoV-2 entry and/or to determine the induced antibody neutralizing activity, including Vesicular 75 
Stomatitis Virus (VSV)-based (17-22), Murine Leukemia Virus (MLV)-based (23-25), and Human 76 
Immunodeficiency Virus (HIV)-based pseudotypes (22, 26).  In this paper, we observed a rather modest 77 
virus infection efficiency with full length spike protein (S)-based pseudovirus. In contrast, deletion of the 78 
last 13 amino acids of the S (SΔCT13) significantly increased spike incorporation into the pseudovirion 79 
and improved infectivity. This optimized SΔCT13-based SARS-CoV-2 neutralization assay will be useful 80 





Deletion of the last 13 amino acids in spike protein enhances SARS-CoV-2 pseudovirus infection 85 
Two main forms of lentiviral vector-based pseudovirus production strategies have been reported, 86 
involving a two-plasmid system or a three-plasmid system (8). The former requires a backbone plasmid 87 
that expresses a full set of HIV-1 gene products except for the HIV-1 envelope (Env), and a second 88 
plasmid that encodes heterologous Env of interest. In contrast, the three-plasmid system separates the 89 
backbone plasmid into two individual constructs, one packaging plasmid and one transfer plasmid (8). 90 
The three-plasmid system was generally regarded as a safer method since multiple virulent genes have 91 
been removed (27). For this reason, we chose the three-plasmid system to generate the SARS-CoV-2 92 
pseudovirus, with which we established a pseudovirus-based neutralization assay. The HIV core 93 
(backbone) is formulated by the packaging plasmid psPAX2 that expresses the HIV gag and pol proteins 94 
and the transfer plasmid pLenti-puro CMV-Luc that harbors the reporter firefly luciferase gene and 95 
essential HIV genomic cis-acting regulatory elements allowing proper encapsulation into the HIV capsid 96 
(28). During preliminary experiments, the SARS-CoV-2 full-length S demonstrated a rather modest viral 97 
entry (2-20 fold above cell-only background, data not shown), which limited its utility in evaluating 98 
neutralizing activity, and thus warranted assay optimization.  99 
Deletion of the last few amino acids in the cytoplasmic tail of SARS-CoV-1 S generated 100 
pseudoviruses with greater infectivity (29). We thus sought similar strategy, deleted the last 13 amino 101 
acids of the SARS-CoV-2 S (termed CoV-2 SΔCT13) and evaluated it in HEK293T-hACE2 cells (Fig. 102 
1A). Interestingly, we noticed significantly increased viral entry for CoV-2 SΔCT13 compared with CoV-103 
2 S (Fig. 1A). Similarly, SARS-CoV-1 full-length (CoV-1 S) and cytoplasmic tail truncated version 104 
(CoV-1 SΔCT13) were included in parallel (Fig. 1A). Both SARS-CoV-1 and SARS-CoV-2 105 
demonstrated augmented virus infection when the last 13 amino acids were ablated, suggesting a possible 106 
general mechanism of the enhancement. In particular, SARS-CoV-2 appeared to rely more on CT deletion 107 
than did SARS-CoV-1, with a 24-fold and 2.4-fold increase of infectivity, respectively. The SARS-CoV-1 108 
S showed more than 200-fold enhancement of viral entry compared with SARS-CoV-2 S, despite the two 109 
6 
sharing the same entry receptor hACE2. To further explore the determinants of the CoV-2 S, we 110 
generated an additional CT variant with the last 6 amino acids deleted (CoV-2 SΔCT6). As shown in Fig. 111 
1A, CoV-2 SΔCT6 displayed similar viral infection efficiency to CoV-2 S, suggesting that a potential 112 
spike incorporation motif exists in the heptad peptides “SEPVLKG”. We further evaluated the spike 113 
protein mediated cell-cell fusion between HEK293T/Spike and TZM-bl/hACE2 cells. Deletion of the last 114 
13 amino acids significantly improved CoV-1 S mediated cell-cell fusion, while CoV-2 SΔCT13 did such 115 
to a less extent (Fig. 1B). Consistent with viral infection result, CoV-2 SΔCT6 induced cell-cell fusion 116 
similarly to CoV-2 S (Fig. 1B). To gain mechanistic insight, we performed western blot analysis of the 117 
proteins expressed in virus producing HEK293T cells. As shown in Fig. 1C, the transfected cells showed 118 
a similar expression level of loading control β-actin and HIV core structural protein p24, suggesting 119 
comparable transfection efficiency. However, the S1+S2 precursor appeared comparable for CoV-1 S, 120 
CoV-1 SΔCT13, CoV-2 S, and CoV-2 SΔCT13, whereas S1 expression in CoV-2 SΔCT13 appeared 121 
higher than that in CoV-2 S, indicating the CT region may affect the spike processing.  122 
We purified viral particles by ultracentrifugation, and analysis by western blot showed that p24 123 
was generally comparable in all the groups, reflecting similar virus production. However, the S1+S2 and 124 
S1 demonstrated a sharp increase (Fig. 1D) for both CoV-1 SΔCT13 and CoV-2 SΔCT13. To confirm, we 125 
also collected the virion-containing supernatants and measured the concentration of HIV-1 p24 and CoV-126 
2 spike by Enzyme-linked immunosorbent assay (ELISA). In line with Western blot data, more spike 127 
proteins as well as higher spike/p24 ratio were detected in CoV-2 SΔCT13 supernatants (Fig. 1E). The 128 
data support a model in which deletion of CT facilitates S incorporation into pseudovirions, thus leading 129 
to elevated viral entry efficiency.  130 
HIV assembles on the plasma membrane, while coronaviruses bud predominantly through ER 131 
(30). We tested whether the enhanced S incorporation into pseudovirions with the ΔCT constructs 132 
resulted from the higher expression of S on the plasma membrane. We performed cell surface staining of 133 
SARS-CoV-1 and SARS-CoV-2 spike proteins. Interestingly, the S and SΔCT13 showed similar 134 
expression levels, as reflected by the geometric mean of S intensity (Fig. 2A and 2B), suggesting that the 135 
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surface expression level unlikely explains the distinct spike incorporation efficiency. Taken together, the 136 
results show that deletion of the last 13 amino acids of S substantially facilitated S incorporation into 137 
pseudovirions and viral entry of SARS-CoV-2 in cells. Based on these data, we selected SARS-CoV-2 138 
SΔCT13 for further study.  139 
140 
SARS-CoV-2 S and SΔCT demonstrated similar sensitivity to neutralization and inhibitor blocking 141 
142 
We next established a neutralization assay with this optimized lentivirus-based pseudovirus (see Materials 143 
and Methods for detailed protocol). To address the question whether the SΔCT13-based pseudovirus 144 
neutralization assay would correlate with the live virus neutralization assay we therefore performed a 145 
direct comparison between the pseudovirus-mediated and live virus-mediated neutralization assay of a 146 
total 67 rhesus monkeys and observed a strong correlation (R= 0.7470; Fig. 3A), reflecting that SΔCT13 147 
maintained the key serologic features of the intact/authentic S. 148 
 Next, we examined the sensitivity of SARS-CoV2 S and SARS-CoV-2 SΔCT13 pseudovirus to 149 
neutralizing antibodies. To this end, we evaluated immunized rhesus monkey serum (N=16) (Fig. 3B) and 150 
purified convalescent IgG from SARS-CoV-2 infected rhesus monkey (Fig. 3C) to CoV-2 SΔCT13 or 151 
CoV-2 S pseudoviruses. Both the immunized serum and convalescent IgG demonstrated similar 152 
neutralization capacity against CoV-2 SΔCT13 and CoV-2 S pseudoviruses (Fig. 3B and 3C). In 153 
particular, we included two additional SARS-CoV-2 S variants, D614G and V367F, which are prevalent 154 
virus variants in the global pandemic (31, 32). All groups demonstrated similar 50% neutralization titers 155 
(NT50 titers) (Fig. 3B). Soluble ACE2 also similarly inhibited CoV-1 S, CoV-1 SΔCT13, CoV-2 S, and 156 
CoV-2 SΔCT13 pseudoviruses (Fig. 3D).  Moreover, these data show the flexibility of this assay in 157 
evaluating neutralization of SARS-CoV-2 variants as they emerge. 158 
Finally, we measured the entry kinetics of CoV-1 S, CoV-1 SΔCT13, CoV-2 S, CoV-2 SΔCT13 159 
with the inhibitor bafilomycin A1 (BafA1). BafA1 targets the vacuolar-type H+ -ATPase and disrupts the 160 
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low pH environment in intracellular organelles (33), which is essential for entry of several low-pH 161 
dependent viruses including coronavirus (Fig. 4A). Both SARS-CoV-1 and SARS-CoV-2 demonstrated a 162 
comparable half maximal inhibitory concentration (IC50) to BafA1 (2-5 nM). To characterize the viral 163 
entry kinetics, viral entry was initially synchronized by cold arrest (spinoculation at 4 oC), which allows 164 
efficient virus binding but not virus-cell fusion. BafA1 was added at 0, 0.5, 1, 2, 3, 4, 6 hours post 165 
spinoculation at a final concentration of 5 nM, and virus titer was determined 48 hours post-infection. As 166 
shown in Fig. 4B, the VSVg-mediated viral entry reached plateau around 2 hours post infection and the 167 
half virus entry time (T1/2) was approximately 25 min, consistent with early reports (34). CoV-1 S and 168 
CoV-1 SΔCT13 pseudoviruses demonstrated slower kinetics, requiring three hours to accomplish 169 
maximal viral entry with T1/2 of about one hour (35). CoV-2 S and CoV-2 SΔCT13 pseudoviruses 170 
exhibited even slower entry, with T1/2 of about 2.5 hours, suggesting the intrinsic differences between the 171 
two coronavirus spikes but no difference between S and SΔCT13 for both viruses. Overall, SARS-CoV-2 172 
S and SΔCT13 demonstrated similar sensitivity to neutralization and inhibition. 173 
174 
Qualification of the SARS-CoV-2 neutralization assay 175 
As qualification experiments, we assessed the following parameters: linearity, limit of detection (LOD), 176 
specificity and reproducibility. Linearity between input virus and luciferase activity was analyzed with 177 
increasing amounts of pseudovirus. As shown in Fig. 5A, solid linearity was achieved between 3.125 and 178 
50 µl virus inoculums (R=0.9894, P<0.0001). Of note, 1 µl of input virus was equivalent to 4 picograms 179 
of HIV-1 p24, as determined by HIV-1 p24 ELISA. To determine sample dilutional linearity combined 180 
with intermediate precision, a pooled, heat-inactivated, high titer COVID-19 human convalescent serum 181 
sample was tested undiluted (neat) and in two-fold serial dilutions ranging from 1:1 to 1:32. These assays 182 
were performed by three different operators over three different days. Linear regression of NT50 titer 183 
plotted as a function of the serum dilution factor suggested strong linearity when the serum concentration 184 
was between undiluted and 1:16 dilution (R=0.9984, P<0.0001; Figure 5B).  185 
9 
Intra- and intermediate assay precision was assessed using the dilutional linearity sample data. 186 
Using pre-specified acceptance criteria of ≤25% coefficient of variation (%CV) to define the upper limit 187 
of quantification (ULOQ), the assay ULOQ was established at an NT50 of 3,153 (Table 1). The limit of 188 
detection (LOD) was assessed by measuring the neutralizing activity of human serum at starting with a 189 
dilutions of 1:20. Serums from other three model species, rhesus macaque, hamster and mouse (naïve 190 
serum) were included for comparison. The LOD was established to 1:23, 1:28, 1:22, 1:20 for human, 191 
rhesus macaque, hamster and mouse, respectively (Fig. 5C). Due to limited availability of high volume 192 
COVID-19 human convalescent serum samples at the time of assay development, undiluted and 1:16 193 
diluted samples were used to approximate intra-assay precision at the high and low ends of the assay 194 
range with samples meeting pre-defined criteria of CV≤25% at each level for each operator (Table 2). 195 
Development of discrete quality control samples that fall in the high (~80%), medium (~50%) and low 196 
(~20%) range for established assay range will subsequently be developed as high volume, high nAb titer 197 
reagents become available. The lentivirus-based neutralization assay demonstrated an overall assay 198 
precision of 15.7%.   199 
With this established SARS-CoV-2 neutralization assay, we tested human serum from pre-200 
pandemic (n=28); early stage of COVID-19 (within 10 days since symptom onset, n=50); and late stage 201 
of COVID-19 (greater than 10 days since symptom onset, n=50).  There was a clear enhanced 202 
neutralizing antibody titer upon infection, with median titers of 20, 218 and 776, respectively (Fig. 5D 203 





Pseudoviruses are versatile and valuable tools for both basic and applied virologic research and 208 
has particular advantages when live virus requires higher biosafety BL3 or BL4 facilities. High 209 
throughput assays using pseudoviruses in BL2 facilities can facilitate rapid testing and development of 210 
SARS-CoV-2 countermeasures such as vaccines. As such, SARS-CoV-2 pseudovirus neutralization 211 
assays are being established. In this manuscript, we describe the development and qualification of an 212 
optimized SARS-CoV-2 pseudovirus neutralization assay for preclinical studies and clinical trials.  We 213 
found that the full length S of two closely related human coronaviruses, SARS-CoV-1 and MERS-CoV, 214 
were readily translatable into a standard pseudovirus system (15) (16).  Full length of SARS-CoV-2 S 215 
mediated low level of infection but can be improved by deleting 13 amino acids in the CT.  216 
We addressed several key issues in the development of this assay.  First, expression of the virus-217 
derived coding sequence in mammalian cells may be suboptimal due to potential codon usage bias (36). 218 
We therefore codon-optimized the entire spike DNA sequence by replacing the GC stretches and 219 
changing into Homo sapiens biased codons and validated its robust expression profile in HEK293T cells 220 
(Fig. 1C).  Second, the viral entry efficiency of SARS-CoV-2 into target cells appear to be intrinsically 221 
inferior to SARS-CoV-1. SARS-CoV-1 exhibited a >100-fold higher entry efficiency than SARS-CoV-2 222 
(Fig. 1A). This may be ascribed to the stronger binding affinity to the receptor hACE2 (37), greater spike 223 
incorporation, accelerated entry kinetics, or other factors. Regardless, we sought to improve SARS-CoV-2 224 
pseudovirus entry into target cells to improve the assay performance. Because partial deletion of the 225 
SARS-CoV-1 CT was reported to increase the viral infectivity (29), we deleted the last 13 amino acids of 226 
the cytoplasmic tail for both SARS-CoV-1 and SARS-CoV-2. Both SARS-CoVs demonstrated greater 227 
viral entry, but this effect was more pronounced for SARS-CoV-2 (Fig. 1A) with a 20-fold enhancement 228 
(22). We also observed a marked increase in SΔCT incorporation into pseudovirions compared with S for 229 
both SARS-CoV-1 and SARS-CoV-2, which correlated with enhanced viral entry. The observed SARS-230 
CoV S protein expressed on the cell surface (Fig. 2) may be due to leakiness of the ER retention upon 231 
overexpression (29). We hypothesize that the enhanced incorporation of SΔCT may reflect higher cell 232 
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surface expression as a result of the removal of a reported ER retention motif KxHxx in the last 13 amino 233 
acids (38) (26). However, we observed the same cell surface expression level for both SΔCT13 and S. In 234 
addition, the SΔCT6 deleted the KxHXX motif while maintained a similar viral entry profile to the S, 235 
arguing against the hypothesis that the spike cell surface expression makes a difference. Interestingly, 236 
when we performed cell-cell fusion assay, where the CoV-2 S and CoV-2 SΔCT13 had comparable 237 
expression level (Fig. 1C and 2), cell-cell fusion events were similarly induced (<2-fold difference, Fig. 238 
1B), suggesting that the functioning of the spike may not be altered by CT deletion. A direct measurement 239 
of viral entry kinetics (Fig. 4B) similarly implicated that truncation of the 13 amino acids unlikely altered 240 
the viral entry properties.  241 
One question regarding the use of SΔCT is whether the C-terminal deletion may have changed 242 
the conformation of the protein, thus potentially altering neutralization sensitivity. There is currently a 243 
lack of direct structural evidence for the CT region of SARS-CoV-2 (39). We observed a strong positive 244 
correlation between the pseudovirus- and live virus-based neutralization assay (Fig. 3A), suggesting the 245 
utility of the pseudovirus neutralization assay. Interestingly, we noticed that a subset of samples with 246 
modest NT50 titers were detected with pseudovirus assay but not under live virus assay, suggesting 247 
different assay sensitivities. Additional studies are warranted to test this hypothesis. Moreover, 248 
immunologic and virologic comparisons between SARS-CoV-2 pseudoviruses with S and S ΔCT13 249 
suggested similar sensitivity to polyclonal antibody, hACE2-mIg and BafA1. Therefore, it is probably 250 
quantitative rather than qualitative changes of the spike in the virion that determine the increased viral 251 
infection rate. Further investigation including detailed structural insight may be warranted. Currently, 252 
VSV-based and lentiviral vector-based pseudovirus systems stand for the primary assays for neutralizing 253 
antibody titer determination (17-22, 26). The intrinsic properties of rapid replication of infectious VSV 254 
accelerate the data generation. While the lentiviral vectors morphologically resemble to the SARS-CoV-2 255 
and may more genuinely reflect the entry process of SARS-CoV-2. 256 
To define performance characteristics of this SARS-CoV-2 pseudovirus neutralization assay, we 257 
performed a series of qualification experiments. The limit of detection for four species appears to be 258 
12 
similar (approximately1:20). Intra- and intermediate precision demonstrated precision levels <25%. 259 
Overall, this optimized and qualified assay has been developed to evaluate SARS-CoV-2 neutralizing 260 
antibody responses in both preclinical and clinical studies.  Moreover, this pseudovirus neutralization 261 
assay is readily adaptable to incorporating S sequences from SARS-CoV-2 variants, such as currently 262 
circulating UK and South African variants. 263 
264 
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MATERIALS AND METHODS 265 
Plasmids, cells, and reagents 266 
 Sequences of full-length spike (S) or 13 amino acids in cytoplasmic tail deleted S (SΔCT) of SARS-267 
CoV-1 (Tor2, GenBank: AAP41037.1) and SARS-CoV-2 (Wuhan/WIV04/2019) were codon optimized 268 
and commercially synthesized (Integrated DNA Technologies, NJ, USA). Synthetic genes were cloned 269 
into the mammalian expression plasmid pcDNA3.1+ (Invitrogen, CA, USA). SARS-CoV-2 S D614G and 270 
V367F variants were generated by site-directed mutagenesis based on SARS-CoV-2 SΔCT. Human 271 
ACE2 genes were commercially synthesized (Integrated DNA Technologies, NJ, USA) and further 272 
cloned into pQCXIP retroviral vector (Cat# 631516, Takara). pHEF-VSVG expressing Vesicular 273 
Stomatitis Virus (VSV) glycoprotein was obtained through the NIH AIDS Reagent Program, Division of 274 
AIDS, NIAID, NIH (Cat# 4693). PsPAX2 (Cat# 12260), pLenti-CMV-Puro-Luc (Cat#17447), and pBS-275 
CMV-gag-pol (Cat#35614) were obtained from Addgene (Boston, MA).276 
HEK293T (ATCC® CRL-11268™), Vero-E6 (ATCC® CRL-1586™) and 786-O (ATCC® CRL-277 
1932™), TZM-bl (AIDS Reagent, Cat# 8129) were maintained in Dulbecco’s modified Eagle’s medium 278 
(DMEM), supplemented with 0.5% penicillin/streptomycin and 5% FBS. HEK293T-hACE2 were 279 
maintained in DMEM, supplemented with 0.5% penicillin/streptomycin, 5% FBS and 1 μg/ml puromycin 280 
(Sigma). 281 
Rabbit polyclonal antibody against SARS-CoV-2 RBD and hACE2 conjugated with mouse IgG Fc 282 
(hACE2-mFc, Cat#10108) was purchased from Sino Biological. Bafilomycin A1 was purchased from 283 
Sigma.  HRP-Conjugated Beta Actin Antibody (Cat# HRP-60008) was purchased from Proteintech. HIV 284 
p24 ELISA kit was ordered from Abcam (Cat# ab218268).  285 
Rhesus and human serum samples 286 
14 
Rhesus macaque anti-SARS-CoV-2 serum was obtained after an adenoviral vector-based vaccination (3). 287 
Serums from 16 animals were collected 4 weeks post single-shot vaccination. The convalescent serum 288 
IgG from our early study (40) was purified and pooled. 12 de-identified SARS-CoV-2 pre-pandemic 289 
human serum samples from Boston, MA were obtained. All human studies were conducted in compliance 290 
with all relevant local, state, and federal regulations and were approved by the Partners Institutional 291 
Review Board (IRB). 292 
Generation of HEK293T-hACE2 stable cell 293 
 The retroviral pseudotypes expressing human ACE2 (hACE2) were generated by co-transfecting 294 
HEK293T cells with pHEF-VSVG, pBS-CMV-gag-pol, and pQCXIP-hACE2 at a ratio of 0.5:1:1. 295 
Viruses in the supernatants were collected every 12 h. The collected viruses were used to transduce 296 
HEK293T cells, and positive cell populations were selected by using 1 μg/ml puromycin. 297 
Production of pseudotyped lentiviral particles 298 
 The SARS-CoV-2 pseudoviruses expressing a luciferase reporter gene were generated in an approach 299 
similar to as described previously (2, 40, 41). 10 µg packaging construct psPAX2, 10 µg luciferase 300 
reporter plasmid pLenti-CMV Puro-Luc, and 5 µg spike protein expressing pcDNA3.1-SARS CoV-2 301 
SΔCT were co-transfected into 5 x 106 HEK293T cells in 10-cm dish with lipofectamine 2,000 (Sigma). 302 
Six hours post transfection, the supernatants were replaced with fresh DMEM (plus 5% FBS). The 303 
supernatants containing the pseudotype viruses were collected 48 hours post-transfection; pseudotype 304 
viruses were purified by filtration with 0.45 µm filter.  305 
Lentiviral luciferase-based neutralization assay 306 
 The SARS-CoV-2 pseudoviruses neutralization assay was generated in an approach similar to as 307 
described previously (2, 40, 41). To determine the neutralization activity of the serum, plasma, or IgG 308 
samples from cohorts, HEK293T-hACE2 cells were seeded in 96-well tissue culture plates at a density of 309 
1.75 x 104 cells/well overnight. Three-fold serial dilutions of heat inactivated plasma samples were 310 
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prepared and mixed with 50 µL of pseudovirus. The mixture was incubated at 37 oC for 1 h before adding 311 
to HEK293T-hACE2 cells. 48 h after infection, cells were lysed in Steady-Glo Luciferase Assay 312 
(Promega) according to the manufacturer’s instructions. SARS-CoV-2 neutralization titers were defined 313 
as the sample dilution at which a 50% reduction in relative light unit (RLU) was observed relative to the 314 
average of the virus control wells. 315 
Live virus neutralization assay 316 
A full-length SARS-CoV-2 virus based on the Seattle Washington isolate was designed to express 317 
luciferase and GFP and was recovered via reverse genetics.  The virus was titered in Vero E6 USAMRID 318 
cells to obtain a relative light units (RLU) signal of at least 10X the cell only control background. Vero 319 
E6 USAMRID cells were plated at 20,000 cells per well the day prior in clear bottom black walled 96-320 
well plates.  Neutralizing antibody serum samples were tested at a starting dilution of 1:40 and were 321 
serially diluted 4-fold up to eight dilution spots. Antibody-virus complexes were incubated at 37 oC with 322 
5% CO2 for 1 hour.  Following incubation, growth media was removed and virus-antibody dilution 323 
complexes were added to the cells in duplicate. Virus-only controls and cell-only controls were included 324 
in each neutralization assay plate. Following infection, plates were incubated at 37 oC with 5% CO2 for 325 
48 hours. After the 48 h incubation, cells were lysed and luciferase activity was measured via Nano-Glo 326 
Luciferase Assay System (Promega) according to the manufacturer specifications. SARS-CoV-2 327 
neutralization titers were defined as the sample dilution at which a 50% reduction in RLU was observed 328 
relative to the average of the virus control wells. 329 
Cell-cell fusion assay 330 
HEK293T cells were transfected with spike-encoding plasmids, along with HIV-1 Tat optimized 331 
expression vector (AIDS Reagent, Cat# 827). Meanwhile, TZM-bl cells were transfected with human 332 
ACE2 plasmid. Twenty-four hours after transfection, cells were cocultured with TZM-bl at 1:1 ratio for 333 
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12 h, lysed, and measured for firefly luciferase activity. All samples were tested in duplicates, and the 334 
results were averaged. 335 
Virus entry kinetics 336 
 1.5 x 104 HEK293T-ACE2 cells/well were seeded in flat 96-well plate at a density of 1.5 x 105 cells per 337 
ml. The second day, 50 µl virus were added into each well, and spun at 1,680g, 30 min, 4 °C. The cell338 
culture plates were transferred into 37 °C incubator immediately after spin, to initiate viral internalization 339 
and infection. 15 µl DMEM medium containing 50 nM BafA1 were added into each well immediately 340 
after spinoculation (0 hour) and 0.5, 1, 2, 3, 4, 6-hour post-temperature shift. 12 hours after culturing, 341 
cells were replenished with fresh DMEM. 48 hours post spinoculation, cells were lysed for luciferase 342 
activity quantification. 343 
Western Blot 344 
 Western blot was performed as previously described (42). Briefly, transfected HEK293T cells were 345 
collected, washed once with icy 1 x DPBS (Sigma), and lysed in Radioimmunoprecipitation assay buffer 346 
(RIPA, Thermo Fisher, MA) for 20 min on ice. The pseudoviral particles were purified from DMEM 347 
culture medium by ultracentrifugation (32,000 rpm, 2 h, 4 0C) and resuspended in 1 x DPBS. The cell 348 
lysates and viral particles were dissolved in sample buffer (4x Thermo Fisher, MA), separated on 4-15% 349 
gradient gel (Bio-Rad), and detected by anti-HIV-1 p24, anti-SARS-CoV-2 RBD, anti-β-actin antibodies.  350 
Cell surface staining 351 
 Cells were washed twice with cold 1x DPBS plus 2% FBS, detached with 1x DPBS containing 5 mM 352 
EDTA, and incubated on ice with the appropriate primary antibodies for 1 h. After three washes with PBS 353 
plus 2% FBS, cells were further incubated with FITC-conjugated secondary antibodies for 45 min. After 354 
two washes, cells were fixed with 2% formaldehyde and analyzed in BD LSRII flow cytometer. 355 
Intermediate precision and dilutional linearity 356 
17 
 A pooled, heat-inactivated, high tittered COVID-19 convalescent serum was undiluted or serially pre-357 
diluted in two-fold dilutions (i.e. neat, 1:1, 1:2, 1:4, 1:8, 1:16, 1:32). Each of these diluted samples was 358 
measured with a starting dilution of 1:20 and further 1:2 serial dilution. These assays were performed by 359 
three independent operators over three different days. 360 
Intra Assay Precision 361 
 In the absence of pre-defined, pre-calibrated quality control samples, two dilutions within the linear 362 
range established in Intermediate precision and dilutional linearity assay were selected to approximate 363 
high and low levels of the range. These values subsequently were used to determine intra-assay precision. 364 
Limit of Detection (LOD) 365 
 The LOD was determined by testing multiple COVID-19 pre-pandemic negative serums. To establish the 366 
LOD, 12 pre-pandemic negative human serums, 28 naïve rhesus monkey serums, 30 naïve hamster 367 
serums and 30 naïve mouse serums were utilized to set the LOD. The LOD of the assay was determined 368 
as the mean of the negative serum samples plus the standard deviation (SD) on the assay nominal scale.  369 
Statistical Analyses 370 
 All statistical analyses were carried out in GraphPad Prism 8 with Student's t-tests or one-way analysis of 371 
variance unless otherwise noted. Typically, data from at least three independent experiments were used 372 
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FIGURE LEGENDS 542 
543 
Fig. 1 | Deletion of the last 13 amino acids in spike protein enhances SARS-CoV-2 pseudovirus 544 
infection.  545 
(A) Lentiviral particles pseudotyped with CoV-1 S, CoV-1 SΔCT13, CoV-2 S, CoV-2 SΔCT13, CoV-2546 
SΔCT6, VSVg or empty (pcDNA3.1) were used to infect HEK293T-hACE2 cells, the firefly luciferase 547 
activity was quantified 48 hours post infection. Data are represented as Mean ± SD of 6-12 replicates. (B) 548 
S, CoV-1 S, CoV-1 SΔCT13, CoV-2 S, CoV-2 SΔCT13, CoV-2 SΔCT6, VSVg or empty (pcDNA3.1) 549 
were co-transfected with HIV-1 Tat-expressing plasmid into HEK293T cells; meanwhile, pQCXIP-550 
hACE2 was transfected into TZM-bl cells. Cells were mixed in a 1:1 ratio and the firefly luciferase 551 
activity was quantified 12 hours post co-culture. Data are represented as Mean ± SD of 6 replicates. (C) 552 
The cell lysates from virus producer cells in (A) were analyzed by western blot. Meanwhile, the viral 553 
particles in supernatants were purified, concentrated and analyzed by western blot (D). Internal control β-554 
actin, HIV-1 p24 and coronavirus spike precursor (S1+S2) and S1proteins were examined in both cell 555 
lysates and viral particles. (E) The concentration of HIV p24 and SARS-CoV-2 spike of indicated 556 
pseudoviruses were assayed by HIV p24 ELISA and SARS-CoV-2 S ELISA. Data of CoV-2 S ΔCT13 557 
was set as 100%. The spike density was quantified as Spike/p24. NS, not significant, ∗∗∗p < 0.001. 558 
559 
Fig. 2 | Cell surface staining of SARS-CoV spike expression.  560 
The same batch of cells was detached by 5 mM EDTA/DPBS digestion buffer and stained with anti-561 
SARS-CoV-2 RBD antibody. The surface expression of spike proteins was analyzed by flow cytometry. 562 
(A) representative flow plot was analyzed by FlowJo software. (B) spike expression was quantified as563 
geometric mean fluorescence intensity. Data are represented as Mean ± SD of 2 replicates. NS, not 564 
significant. 565 
566 
Fig. 3 | SARS-CoV-2 ΔCT13 maintains the same sensitivity to neutralization and inhibition. 567 
24 
 (A) Correlation of pseudovirus NAb titers and live virus NAb assays in vaccinated macaques (N=67).  568 
Red line reflects the best-fit relationship between these variables.  P and R values reflect two-sided 569 
Spearman rank-correlation tests. (B) NT50 titer of vaccinated macaque serums (N=16) against SARS-570 
CoV-2 S , S ΔCT,  S ΔCT D614G and S ΔCT V367F pseudovirus. Red bar indicates the median response. 571 
Inhibition curve of pooled purified IgG from convalescent macaques (C), hACE2-mFc (D) against SARS-572 
CoV-1 S, SARS-CoV-1 S ΔCT13, SARS-CoV-2 S, SARS-CoV-2 S ΔCT13 or VSVg pseudovirus were 573 
generated by pre-incubating indicated antibody or inhibitors for one hour and performing virus infection 574 
in HEK293T-hACE2 cells. Dotted lines interpolate 50% inhibition or neutralization. Data are represented 575 
as mean ± standard deviation of technical triplicates. 576 
Fig. 4 | SARS-CoV-2 S ΔCT13 maintain the same entry kinetics as the SARS-CoV-2 S. 577 
(A) Inhibition curve of BafA1 against CoV-1 S, CoV-1 S ΔCT13, CoV-2 S, CoV-2 S ΔCT13 or VSVg578 
pseudovirus were generated by pre-incubating indicated antibody or inhibitors for one hour and 579 
performing virus infection in HEK293T-hACE2 cells. Dotted lines interpolate 50% inhibition or 580 
neutralization. (B) The viral entry kinetics of the five pseudoviruses were analyzed by BafA1 block assay. 581 
The viruses were bound to target cells at 4 0C by spinoculation and then placed at 37 0C allowing virus 582 
endocytosis and fusion. The entry inhibitor BafA1 (final concentration 5 nM) was added as indicated time 583 
points. 12 hours post treatment, the cells were replenished with fresh DMEM. Viral entry was normalized 584 
to mock (DMSO) treated infection group. Data are represented as mean ± standard deviation of technical 585 
triplicates. 586 
587 
Fig. 5 | Qualification of the SARS-CoV-2 neutralization assay. 588 
(A) The linearity between the virus input volume and firefly luciferase activity was analyzed (N=5). (B)589 
The linearity between the human serum dilution and NT50 titer was demonstrated (combined data of 590 
three operators, with three repeats of each, N=9). P and R values reflect two-sided Pearson rank-591 
correlation tests. (C) Limit of detection of established neutralization assay was validated by examining 592 
25 
serums from COVID-19 pre-pandemic human donors (N=12), SARS-CoV-2 negative rhesus macaques 593 
(N=28), naïve hamsters (N=30) and naïve Balb/C mice (N=30). Serums were 1:20 diluted and then 594 
undergone 1: 2 serial dilution, data demonstrated 50% neutralization titer. (D) human serums from pre-595 
pandemic (n=28); early stage of COVID-19 (within 10 days since symptom onset, n=50); late stage of 596 
COVID-19 (greater than 10 days since symptom onset, n=50) were applied into established SARS-CoV-2 597 
neutralization assay. Data demonstrated as 50% neutralization titer and red bar reflects the median titer. 598 




Table 1 | Intermediate assay precision with pooled convalescent human serum 602 



















Run 3 GeoMean Std Dev %CV 
Undiluted 2370 3290 3411 3047 2788 3714 4024 2774 3289 3153.1 508.2 16.1 
1:1 1488 1410 1710 1567 1498 1907 2447 1516 2086 1708.5 346.3 20.3 
1:2 763 912 983 704 846 983 1039 1042 1054 916.4 128.4 14.0 
1:4 391 464 445 364 527 481 462 503 434 449.6 51.3 11.4 
1:8 193 210 166 168 224 254 251 168 177 198.3 35.4 17.8 
1:16 111 101 111 75 97 99 98 83 87 95.1 12.2 12.8 




Table 2 | Intra-assay precision with pooled convalescent human serum 605 
Operator 1 NT50 
Serum dilution Run 1 Run 2 Run 3 GeoMean Std Dev %CV 
Undiluted 2370 3290 3411 2985 569.3 19.1 
1:16 111 101 111 108 5.8 5.4 
Operator 2 NT50 
Serum dilution Run 1 Run 2 Run 3 GeoMean Std Dev %CV 
Undiluted 3047 2788 3714 3160 477.7 15.1 
1:16 75 97 99 90 13.3 14.9 
Operator 3 NT50 
Serum dilution Run 1 Run 2 Run 3 GeoMean Std Dev %CV 
Undiluted 4024 2774 3289 3324 628.2 18.9 
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